Hematologic Cancers
TON - March 2018, Vol 11, No 1 - Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.
Beth Faiman discusses the difficulty of keeping abreast of all the new multiple myeloma treatments and how she personally stays up to date on all of the information.
Beth Faiman reflects on the considerations involved with managing patients who have experienced multiple myeloma relapses.
Beth Faiman sees daratumumab as a game changer for patients with multiple myeloma.
Beth Faiman reviews the steps she takes upon introducing patients to daratumumab.
Beth Faiman gets questions from her patients about daratumumab on an almost daily basis. Find out what their most asked questions are.
Patients with newly diagnosed multiple myeloma have different needs than pateints relapsed/refractory disease, and Beth Faiman addresses what some of these needs are.
Beth Faiman explains how she identfies side effects that her patients are experiencing in order to open the lines of communication to better address other issues the patient may not be aware of.
Beth Faiman discusses why it's important to communicate with and educate patients so that they can better manage their symptoms before they become more severe.
Beth Faiman expresses her main concerns regarding new treatments being studied to treat multiple myeloma.